Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBT Margin (2016 - 2025)

Historic EBT Margin for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to 10.71%.

  • Arrowhead Pharmaceuticals' EBT Margin rose 70153100.0% to 10.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 23.37%, marking a year-over-year increase of 259788100.0%. This contributed to the annual value of 6.21% for FY2025, which is 172537500.0% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported EBT Margin of 10.71% as of Q4 2025, which was up 70153100.0% from 14.08% recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBT Margin peaked at 68.11% during Q1 2025, and registered a low of 7004.6% during Q4 2024.
  • Its 5-year average for EBT Margin is 813.05%, with a median of 165.54% in 2021.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' EBT Margin plummeted by -38388100bps in 2023, and later skyrocketed by 70153100bps in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' EBT Margin stood at 229.13% in 2021, then soared by 71bps to 66.82% in 2022, then plummeted by -5745bps to 3905.63% in 2023, then plummeted by -79bps to 7004.6% in 2024, then surged by 100bps to 10.71% in 2025.
  • Its last three reported values are 10.71% in Q4 2025, 14.08% for Q3 2025, and 644.97% during Q2 2025.